Mr. David Caumartin is Managing Director of Theraclion, a French listed innovative company, specializing in high technology medical equipment using therapeutic ultrasound, since September 2014. Previously, David developed his experience for 14 years at GE Healthcare in EMEA and in the United States, in sales, marketing and the development of new products, scanners and conventional radiology. He led the global mammography business from 2007 to 2011. In 2012, David joined Alstom Thermal Power as Vice President Strategy-Merger & Acquisition. He graduated from Telecom Paris and holds a Master's degree in Fundamental Physics from Paris Diderot University. He is certified Six Sigma Master Black Belt. Based on the most advanced technologies, Theraclion designs and markets Echopulse®, an innovative echo-therapy solution that enables the non-invasive tumor ablation using ultrasound-guided High Intensity Ultrasound energy. In addition to the treatment of benign tumors of breast adenofibromas and thyroid nodules for which Theraclion has the CE mark, the company, in partnership with the University of Virginia (UVA, USA), is evaluating the potential of the combination treatment of echotherapy delivered by the Echopulse system with pembrolizumab, an immunotherapy molecule in metastatic breast cancer & solid tumours. Theraclion has also recently completed feasibility and registration trial for Variscose Veins Treatment that is CE Mark under the Sonovein® brand since 2019 and currently launching second generation Vein device. USA clinical trial for veins is anticipated 1H’2021.